Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Tisotumab Vedotin-tftv in Metastatic Carcinoma to the Uterine Cervix: NCT06952660 Clinical Landscape Report 2026
16 October 2026
NCT06952660 clinical landscape for Metastatic Carcinoma to the Uterine Cervix: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Daratumumab biosimilar (Celltrion) in Relapse multiple myeloma: NCT06952478 Clinical Landscape Report 2026
16 October 2026
NCT06952478 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Clobetasol Propionate in Dermatitis, Atopic: CTRI/2025/05/086168 Clinical Landscape Report 2026
16 October 2026
CTRI/2025/05/086168 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-BCMA and CD19 CART(Anhui Provincial Hospital) in B-Cell Leukemia: NCT06961669 Clinical Landscape Report 2026
16 October 2026
NCT06961669 clinical landscape for B-Cell Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Hydroxychloroquine Sulfate in Ovarian Serous Tumor: NCT06971744 Clinical Landscape Report 2026
16 October 2026
NCT06971744 clinical landscape for Ovarian Serous Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NG-01 in Multiple Sclerosis, Secondary Progressive: NCT06961383 Clinical Landscape Report 2026
16 October 2026
NCT06961383 clinical landscape for Multiple Sclerosis, Secondary Progressive: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
DT-2216 in Recurrent ovarian cancer: NCT06964009 Clinical Landscape Report 2026
16 October 2026
NCT06964009 clinical landscape for Recurrent ovarian cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zasocitinib in Plaque psoriasis: NCT06973291 Clinical Landscape Report 2026
16 October 2026
NCT06973291 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
VC-005 in Dermatitis, Atopic: NCT06974292 Clinical Landscape Report 2026
16 October 2026
NCT06974292 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Utidelone in Platinum-Resistant Ovarian Carcinoma: NCT06973421 Clinical Landscape Report 2026
16 October 2026
NCT06973421 clinical landscape for Platinum-Resistant Ovarian Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
AC-201 in Plaque psoriasis: NCT06972888 Clinical Landscape Report 2026
16 October 2026
NCT06972888 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Ovarian Cancer: NCT06976892 Clinical Landscape Report 2026
16 October 2026
NCT06976892 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.